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rely on intracellular modulators of cell function will have inevitable 
limitations in efficacy based on the inefficiency of gene transfer. 
Recognizing this limitation, we devised astrategy that involved a 
naturally occurring endogenous substance that is highly diffusible 
and able to modulate the function of neighboring nontransfected 
cells within the vessel wall. This paracrine approach to gene therapy 
effectively amplifies the efficiency of the gene transfer in modulat- 
ing vascular function and structure. Our choice of genes that 
promote the generation ofthe vasodilator nitric oxide was based on 
its salutary effecti on the vascnlature, including its capacity to 
inhibit platelet aggregation, leukocyte adhesion, vascular smooth 
muscle cell growth and migration, and matrix production. Under 
certain circumstances nitric oxide may also promote selective cell 
deletion by inducing apoptosis. The efficacy of the gene transfer of 
nitric oxide synthase III confirms the utility of using a paracrine 
gene transfer strategy as a therapeutic approach to modulating 
vascular function and structure. Moreover, this experimental p- 
proach as provided new mechanistic insights into the biologic role 
of nitric oxide as an endogenous inhibitor of vascular lesion 
formation. Overall, the normalization of endothelial function by 
either genetic engineering strategies or more conventional phar- 
macologic approaches appears to be a particularly effective ap- 
proach to modulating the course of vascular disease. 
Gary If. Gibbons, MD 
Stanford University 
Stanford, Calif. 
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ANT ISENSE STRATEGIES  FOR CONTROLL ING 
THE VASCULAR RESPONSE TO IN JURY 
Antisense oligonucleotides have been proposed as being of impor- 
tance in treating and examining proliferative vascular diseases 
because of their potential ease of fabrication and intuitive intellec- 
tual appeal. Unlike complex proteins, oligonucleotides can be 
readily synthesized in a short time and in large bulk. The concept 
behind their use is especially intriguing iven the disappointing 
results of a multitude of other promising agents. Calcium channel 
blockers, antllipid agents, growth factors and their antagonists, 
antiplatelet agents, and antlinflammatory agents, among others, 
have all failed to inhibit ultimate neointimal hyperplasia n clinical 
trials despite initial enthusiastic data from experiments in culture 
and with lower anima! species. One major eason may be that higher 
animal species and human beings are not simple systems like 
isolated cells in culture. Redundant biologic processes enable the 
organism to recover from blockade of a single, specific pathway. An 
approach that seeks to identify and inhibit the common final 
pathway irrespective of the initial stimulus is therefore immensely 
appealing. Antisense approaches nable such an intervention, and 
a number of especially promising preliminary reports have been 
published. Yet the field remains incompletely defined and subject to 
substantial controversy. In particular it is still not clear which genes 
are best argeted incombating proliferative and accelerated vascular 
diseases; how to best direct, dose, and administer the antisense 
compounds to a given target sequence; and exactly how antisense 
oligonudeotides xert heir effects. We will now review these issues 
and controversies and attempt o offer a consensus opinion. A 
number of excellent reviews have recently been published that 
examine the field in full, and the reader is referred to them for more 
complete analysis beyond the scope of this manuscript. 1-4 
Identification of target 
It is now understood that intimal hyperplasia s the end result 
and inevitable consequence of a coordinated sequence of cellular 
events that include platelet adhesion, activation, and aggregation; 
the balance of endothelial integrity and dysfunction; leukocyte 
adhesion and transmigration; monocyte/macrophage transmigra- 
tion and transformation; lipid metabolism, including oxidation and 
methylation; growth factor and mitogen release, binding, internal- 
ization, and cell activation; smooth muscle cell migration and 
proliferation; and extracellular matrix production. Vascular smooth 
muscle cell activation is accompanied by the induction of several 
intracellular signal pathways, up-regulation of multiple receptors, 
and overexpression f a number of genes. The system's complexity 
and redundancy makes it difficult o envision asingle intervention 
that can control the entire process. Inhibition of one receptor may 
be overwhelmed by up-regulation or overexpression f another, 
and blockage of one pathway may be circumvented by overstimu~ 
lation of parallel, albeit circuitous, routes. Thus, many investigators 
have sought o inhibit one or more of the critical genes involved in 
cell-cycle progression. These have included enzymes involved in 
DNA and nucleotide synthesis, DNA binding proteins and tran- 
scription factors such as c-myb and c-myc, 5-12 and cell-cycle 
regulators including cdc-2, cdk-2, and the cyclins. 13-16 It is not yet 
dear whether the inhibition of one of these cycle controllers alone 
will suffice to limit the full extent ofintimal hyperplasia after injury. 
Indeed, the concomitant administration of antisense to cdc-2 
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kinase and the cyclin, proliferating ceil nuclear antigen exerted a
synergistic effect.13 Ultimately, the least oxic and most efficient use 
of antisense technology may require that we mimic current com- 
binatorial practice of antineoplastic regimens, wherein the potency 
of multiple drugs is greater than the sum of their individual effects. 
Pharmacoldnetics 
Assuming that an ideal target mRNAis identified and antisense 
oligomer fabricated, there are still a multitude of factors that 
determine the effect. An antisense oligonucleotide s quence can 
fail to have an effect on its target gene because it is degraded or 
denatured before cell interaction, can not enter the target cell, does 
not effectively bind the target sequence, can not overcome the 
constant expression of target mRNA, and, though it hybridizes the 
mRNA segment, can not inhibit protein expression to a significant 
extent. Although the judicious selection of target and oligonucle- 
otide sequence can alleviate some of these concerns, others remain. 
These issues might best be grouped under the general rubric of 
pharmacokinetics, for they deal primarily with issues of dose, 
delivery, distribution, clearance, and elimination. The native ollgo- 
nucleotide xists as a phosphodiester and is intensively sensitive to 
degradation by ubiquitous nucleases. First and foremost, his limits 
the potential interaction of the oligonucleotides with their targets 
and the duration and impact of their effect. At the same time, 
however, the breakdown degradative products may actually coun- 
teract he antisense ffect. Individual nucleotides and nucleosides 
can increase cell proliferation and migration. 17-19 As a result, great 
effort has been applied to prolonging the stability and half-life of 
the nucleotide chains and in creating modes of delivery that 
prolong and sustain release. Such methods might actually circum- 
vent the problems associated with reduced cellular uptake. 
Chemical modification. Although the degradative nucleases 
that can attack antisense oligonucleorides are principally exonu- 
cleases, blockade of sequence t rmini alone is insufficient to protect 
oligonucleotide chains. 2° Further modification is required to pro- 
tect against endonucieases, for even small amounts of these 
enzymes can have profound effects. It has been calculated that an 
oligonucleotide n ed only be 12 bases in length to hybridize to one 
target site on a genome. 2° Thus if longer oligomers are cleaved, 
dodecamer oligonucleotides can bind to undesired target sites and 
produce unexpected results. Although it is possible to modify any 
of the component elements of the nucleotide, including the base, 
sugar, or phosphodiester group, it is best o leave the bases intact so 
as to preserve Watson-Crick pairing. Thus, the most common 
chemical alterations involve substitution of a methyl group or sulfur 
atom for one of the nonbridging oxygens in the phosphodiester 
bonds, creating methylphosphonate nd phosphorothioate ana- 
logs, respectively. Whereas the latter are negatively charged and 
water soluble, the former are uncharged and more lipophilic; and 
though both are lO-fold to lO00-fold less sensitive to nuclease 
degradation, either is entirely resistant to such processes. The 
greater concern, however, isthat such modification may change the 
natural activity seen with the phosphodiester. Indeed, as will be 
discussed below, the half-life of the phosphothioate ollgomers may 
be prolonged, but excess charge may also lead to binding of 
proteins uch as growth factors and subsequent interference with 
other nonspecific cell functions. 
Delivery systems. To overcome issues of half-life a variety of 
means have been proposed for the sustained release of these 
oligonucleotides. Microinjection techniques insure cell entry in 
culture 21 but can not be used in vivo. At least five different means 
of drug administration have been used in animal experiments, 
including individual injections of the modified oligonucleotide 
alone, the oligonuclcotide complcxed to linker conjugates, or the 
sustained release of the oligonucleotidcs from intravascular lipo- 
somes, extravascular polymeric drug delivery systems, or generi- 
cally altered ceils. Our expcricnce with the sustained delivery of two 
protooncogencs supports the importance of delivery mode, irre- 
spective of how achieved) ° Wc examined the intermcdiate-carly 
gene, c-myc, and the iate-GI genes, c-myb, when released from 
either poloxamer gels or ethylene-vinyl acetate copolymcr (EVAc) 
matrices. Poloxamcr gelling depends on the correct relative con- 
ccntrations and the molecular weights of the copolymcr mono- 
mers, oxycthylcnc and oxypropylcne, and gel dissolution is con- 
ccntrarion-depcndcnt. For most gels used, thc bulk of incorporated 
drug is rdeascd within 24 to 72 hours.l°'22 In contrast, coated EVAc 
matrices provide near zero-order release 23-2s for well beyond the 14 
to 28 day duration of a typical vascular injury animal experiment. 
Antisensc oligonuclcotidcs to either protooncogcnc supprcsscd 
smooth muscle ceil proliferation in culture identically whether 
simply injected as a bolus, gel-released in culture for only the first 
few hours or matrix-released forthe duration of cell growth. In vivo 
effects were far more sensitive to the duration of  exposure. Whereas 
both iimitcd gel-release and sustained polymer device administra- 
tion of c-myb antisensc oligonuclcoride sequences inhibited inti- 
mal hyperplasia 2 weeks after denuding injury to the rat carotid 
artery, only the more prolonged EVAc matrix release of antiscnsc 
oligonuclcotidc toc-myc was effective. The short-course gel rdeasc 
of c-myc antisensc had no discernible ffect. 1° 
The short course of c-myc oligomer elease failed to inhibit 
ncointimal hyperplasia becansc of the cyclical expression of the 
target oncogene. Whereas c-myb is expressed early and txansicnfly 
in the course of the proliferation of vascular smooth muscle cells, 
c-myc has a more prolonged and cyclical expression. 26-32 Miano ct 
el. 33 showed a biphasic pattern of expression with peaks at both 6 
hours and 7 days after arterial injury. As a result, cultured smooth 
muscle cells begin to proliferate normally after media containing 
antisensc oiigomcrs is replaced with fresh media devoid of the 
antiscnsc sequcnccs, n'3~ and smooth muscle cells vitally transfccted 
with human c-myc eDNA can constitutively express enough 
protein to ritrate out the growth-inhibitory effect of the antiscnsc 
oligonucleotidc. 7 Poloxamcr anfiscnsc release successfully inhib- 
ited early cellular events but could not regulate latcr cell events. 
Within 24 hours of arterial injury, short-term c-myc anti-sense 
gcl-releasc rcduced mBaNA levels in the tunica media 2.5-fold and 
c-myc expression by 98.8%. As a result, the number of proliferating 
cells was decreased 6.5-fold 3 days after injury. One wcck after 
injury, however, the number of cells expressing the oncogene was 
only 29.6% suppressed, and the extent of intimal hypcrplasia was 
70% ofcontroivalucs. Only prolonged release of the same oligomcr 
scqucnces from the EVAc matrices obliterated protein expression 
for the duration of the experiment and reduced infimal hyperplasia 
at 2 weeks after injury l 1.1-fold. 
Thus, the effectiveness of antiscnse suppression of neointimal 
proliferation depends on the time course of target gcnc expression 
as well as the idnetics of oligonucleotide delivery. So that single- 
dose administration of antiscnse to some protooncogenes can 
forever prevent cell cycling, 7,14,3s but other genes may require more 
prolonged inhibition to achieve the same effect. With genes uch as 
c-myb, which are expressed early and transiently inthe course of the 
proliferation of vascular smooth muscle cells, single delivery can 
suffice, but when, such as with c-myc, 26-3a expression is more 
prolonged and cyclical expression continuous delivery is critical. 
There is increasing evidence that single-dose therapy fails for other 
classes of drugs proposed to combat proliferative vascular disease. 
We recently demonstrated that although continuous intravenous or
pcrivascular dministration ofhcparin virtually obliterated intimal 
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hyperplasia after vascular injury, periodic administration f the same 
heparin compound, at the same total dose, actually exacerbated 
injury. 36 The need for continuous delivery in human beings is 
scientifically intriguing but logistically prohibitive. The technology 
ofimplantable devices has yet to reach the stage were prolonged, 
continuous delivery from these types of devices is possible, and 
repeated injections are doomed to noncompliance and failure. 
Innovative approaches, uch as those proposed by Dzau and 
others, 14 may be needed in this setting. The cellular uptake of 
oligonucleotides ncapsulated within liposomes coated with inac- 
tivated hemagglutlnating virus was markedly enhanced and signifi- 
cantly stabilized and sustained) 4 Luminal delivery could be ob- 
tained and a host of oligonucleofides u ed within this liposomal 
vehicle. 
The optimum means of administering antisense oligonude- 
otide sequences has yet to be defined and may well be idiosyncratic, 
with different needs dependent on target gene, oligonucleotide 
sequence, antisense dose, and extent of vascular injury. Nonethe- 
less, it certainly appears that in-depth evaluation of antisense 
pharmacokinetlcs-matched target gene expression is a virtual 
necessity if these compounds are to be expected to play a major 
clinical or research role. 
Specificity of effect 
The flip-side to the possibility that antisense oligonucleotides 
may not inhibit the intended biologic processes i the absence of 
specificity. Antisense hybridization tonontarget sequences, nonan- 
tisense suppression fproliferation, and other cytotoxic effects limit 
the utility of the antisense approach. There is a curious double- 
edged element to antisense binding. On the one hand a two- or 
three-base shift in the target can be absolutely critical to effective 
inhibition ofgene expression. 9,34 On the other hand, hybridization 
to and degradation of mRNA sequences does not require perfect 
aligument J Thus, it is possible to construct and defiver antisense 
oligonucleotide sequences that are precisely homologous to 
mRNA segments and have no biologic effect, or sequences with 
only moderate homology that can degrade targeted and nontar~ 
geted mRNA by means of antisense and nonantisense binding. 
Specificity of binding to target mRNA sequences rises with 
the dose and length of the antisense strands, but so does hybtid- 
izatlon with other mRNAs, and nonspecific binding of proteins and 
other compounds, as well. Phosphorothioate oligonucleotides 
directly bind heparin-binding growth factors in a length-dependent 
and concentration-dependent fashion, 3s and soluble CD-4 in a 
similar length-dependent, but relatively sequence-independent, 
fashion. 39 In a curious bimodal fashion, low doses of phospho- 
rothioate oligonucleotides can induce ribonuclease H activity to 
cleave mRNA in its complex with DNA, whereas at higher doses 
oligomers can directly bind to and inhibit ribonuclease catalytic 
activity. 4° Finally, specific oligonucleotide sequences, including 
four consecutive guanosines and specific flanking sequences, appear 
to inhibit proliferation related more to aptameric than antisense 
binding) TM 
Yet, all of these considerations a ide, when doses and se- 
quence lengths are controlled and consecutive guanosine resi- 
dues avoided, there still seems to be a specific antisense effect for 
a number of genes. Time and again, intimal mass, smooth muscle 
cell proliferation, c-myc, mRNA, and protein levels have been 
inhibited in rat, rabbit, and pig carotid, iliac, and carotid arteries 
by antisense sequences without the guanosine quartet but not 
by sense, scrambled, and mismatched oligonucleotide se- 
queneesp,7,9,~o,i2 ~6,34,42,43 Thus antisense technology remains a 
potent but controversial tool for biomedical research. It is likely 
that we will ultimately find that everyone is correct. Antisense 
oligonucleotides dohybridize to specific mRNA sequences, but at 
increased oses, sequence lengths, and for particular nucleotide 
repeats, other nonspecific effects may be noted. If we can under- 
stand the outstanding issues regarding the mode ofoligonucleotide 
action, we might be able to harness this powerful approach to 
further delineate the pathophysiology of a variety of disease states 
from neoplasia to hyperplasia and to suggest new treatments for 
their cure. 
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ANTISENSE C-MYC THERAPY 
Antisense technology evolved from the desire to specifically inhibit 
tumor cell growth without bringing about file systemic toxicity 
seen with conventional cytotoxic and biologic agents. Similarly, the 
goal of controlling neointimal hyperplasia requires the inhibition of 
a specific cell population. SMC proliferation is one of the major 
causes for failure of both percutaneous and traditional vascular 
interventions in the 2 month-to-3 year postoperative period. 
Control of this response in human trials remains elusive) The 
specificity and more central site of action afforded by antisense 
therapy could prove a useful adjunct in improving the long-term 
outcome of vascular interventions. 
The myc gene was first identified as the viral oncogene of avian 
myelocytomatosis.2 Subsequently, it was identified in the vertebrate 
genome as c-myc. 3 The gene sequence ishighly conserved across 
vertebrate species, and rearrangements have been found in numer- 
ous animal and human cancers. 4's The products of the myc gene are 
a pair of DNA-binding phosphoproteins localized to the nucleus 
that recognize a short segment of DNA upstream from its own 
gene. 6
The exact role these protein products play in cell proliferation 
is unknown. Their importance appears to be related to DNA 
synthesis. Inhibition of DNA, but not RNA, synthesis can be 
achieved with a monoclonal antibody to c-myc protein. This 
inhibition is similar to that obtained with antibodies to DNA 
polymerase alpha. 7During the G O phase, myc mRNA is absent 
from the nucleus; however, it is the earliest mRNA to accumulate 
when quiescent cells are stimulated to proliferate, s-i° Only low 
levels of the c-myc phosphoproteins appear to be needed to induce 
cell proliferation i nontransformed cells, and their half-life is very 
short) 1 Germane to this discussion are the specific effect ofc-myc 
phosphoproteins on vascular smooth muscle cells (VSMC). Mito- 
